|Systematic (IUPAC) name|
|Licence data||EMA: , US FDA:|
|Bioavailability||52% (active metabolite)|
|Protein binding||50% (active metabolite)|
|Metabolism||Hepatic (CYP2D6- and 3A4-mediated)|
|Half-life||7–8 hours (active metabolite)|
|Excretion||Renal (70%) and fecal (7%)|
|(what is this?)|
Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB). It was approved by the European Medicines Agency in April 2007, the US Food and Drug Administration on October 31, 2008  and Health Canada on February 9, 2012.
Fesoterodine has the advantage of allowing more flexible dosage than other muscarinic antagonists. Its tolerability and side effects are similar to other muscarinic antagonists and as a new drug seems unlikely to make great changes in practices of treatment for overactive bladder.
- "Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder – Pfizer To Acquire Exclusive Worldwide Rights". Medical News Today. 17 April 2006.
- "Toviaz: European Public Assessment Report, Revision 3 - Published 02/06/08". European Medicines Agency. 2 June 2008.
- "Pfizer's Toviaz (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder" (Press release). Pfizer Inc. 2008-10-31. Retrieved 2008-11-06.
- Notice of Decision for TOVIAZ
- Vella, M.; Cardozo, L. (2011). "Review of fesoterodine". Expert Opinion on Drug Safety 10 (5): 805–808. doi:10.1517/14740338.2011.591377. PMID 21639817.